TELO

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile.MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1 (Telomir-Zn), for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).The IND submission includes data from com

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

10-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

DEFM14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

DEFA14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity.MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic drivers of cancer, today announced new in vitro data demonstrating that Telomir-1 (Telomir-Zn) induces broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer (TNBC).Iron-rescue experiments confirmed that the observed tumor cell mortality is iron-dependent, directly supporting Telomir-Zn's propos

SCHEDULE 13G/A - Telomir Pharmaceuticals, Inc. (0001971532) (Subject)

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental biological mechanisms implicated in cancer, aging, and degenerative disease, today announced new cellular study results demonstrating that Telomir-1, in the form of Telomir-Zn, induces a rapid and coordinated intracellular redistribution of zinc and i

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

PRER14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced results from a completed efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (TNBC). The study was conducted in collaboration with BioReperia using its ZTX® ONCOLEADS platform.In one

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir).The studies were conducted as part of the Company's ongoing IND-enabling prog

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

PRER14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today reported new preclinical findings demonstrating that its lead therapeutic candidate, Telomir-1, reduced PSA (prostate-specific antigen) levels in androgen-responsive human prostate cancer cells (LNCaP).PSA is one of the most widely used and FDA-accepted clinical bio

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ACCESS Newswire / November 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapies targeting the epigenetic and metabolic roots of cancer, aging, and age-related disease, today announced new in vitro findings showing that its investigational compound Telomir-1 kills aggressive human leukemia (HL60) cells.In this study, HL60 leukemia cells were treated with Telomir-1, which produced a clear

8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

PREM14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)